StockData
Incyte Corp logo

Incyte Corp (INCY) KPIs and segments

INCYNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 13/3091% above fair value
$117.80−1.29 (-1.08%)

Close on Nov 18, 2026Market cap $24.01BP/E 62.7Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Incyte · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Incyte: 31 chỉ số vận hành, trong đó có Jakafi Paid Patient Demand Growth (YoY %), Opzelura Commercial Revenue Growth và Jakavi Ex-U.S. Partnered Royalty Revenue Growth, lấy từ 223 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
JAKAFI($M)
827817758828791764709773741706572695
OPZELURA($M)
25545014320718816411916213912285.7
Product royalty revenues($M)
191175151184171151131159157137126150
JAKAVI($M)
13212410613012611092.111411699.389.6
NIKTIMVO($M)
67.460.355.156.045.836.213.60000
ZYNYZ($M)
58.349.941.431.722.78.923.011.370.690.650.470.58
MINJUVI/MONJUVI($M)
54.653.749.241.942.031.129.632.831.431.123.98.99
Milestone and contract revenues($M)
49.811.21710045500180252
OLUMIANT($M)
39.138.536.437.133.530.834.831.730.6
OLUMIANT Royalty Revenues($M)
38.534.831.730.640.4
ICLUSIG($M)
33.534.435.534.237.632.729.527.429.726.930.327.1
PEMAZYRE($M)
21.223.422.522.722.218.423.120.720.317.720.7
Other($M)
12.65.333.253.471.861.291.270.330.410.880.55
TABRECTA($M)
6.836.695.987.146.516.636.416.295.935.305.23
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)4
United States($M)
1,4351,5601,1711,4251,2611,1329821,0871,070989828
Europe($M)
10710592.476.010078.868.688.966.553.651.5
Other countries($M)
14.98.808.786.084.414.352.732.511.371.141.20
Jakafi Paid Patient Demand Growth (YoY %)(%)3
12.0%9.0%6.0%11.0%10.0%8.0%10.0%14.0%10.0%9.0%5.0%
Jakafi Net Product Revenue Growth — As Reported (YoY %)(%)
4.0%7.0%7.0%7.0%7.0%8.0%24.0%11.0%16.0%3.0%-1.0%7.0%
Jakafi Full-Year Net Product Revenue Guidance — Low Bound($M)
3,2203,2203,2203,2203,0503,0002,9502,9252,7402,710
Jakafi Full-Year Net Product Revenue Guidance — High Bound($M)
3,2703,2703,2703,2703,0753,0503,0002,9752,7702,750
Opzelura Commercial Revenue Growth — As Reported (YoY %)(%)3
36.0%173.0%20.0%28.0%35.0%35.0%38.0%48.0%52.0%52.0%52.0%78.0%
Opzelura International (Ex-U.S.) Net Product Sales($M)
46.942.936.729.844.432.323.5
Opzelura Full-Year Net Product Revenue Guidance — Low Bound($M)
1,1001,050750750630630630630
Opzelura Full-Year Net Product Revenue Guidance — High Bound($M)
1,1201,100790790670670670670
Jakavi Ex-U.S. Partnered Royalty Revenue Growth — Constant Currency (CER YoY %)(%)16
6.0%12.0%5.0%8.0%4.0%7.0%6.0%13.0%20.0%14.0%19.0%14.0%
Jakavi Ex-U.S. Royalty Revenue Growth — As Reported (YoY %)(%)
5.0%13.0%15.0%14.0%9.0%10.0%3.0%10.0%20.0%10.0%17.0%14.0%
Olumiant Global Royalty Revenue Growth — Constant Currency (CER YoY %)(%)
8.0%16.0%12.0%2.0%4.0%4.0%6.0%-3.0%22.0%4.0%-8.0%12.0%
Olumiant Global Royalty Revenue Growth — As Reported (YoY %)(%)
5.0%15.0%18.0%12.0%7.0%6.0%1.0%-5.0%17.0%-1.0%-10.0%13.0%
Tabrecta Global Royalty Revenue Growth — As Reported (YoY %)(%)
5.0%1.0%-7.0%14.0%10.0%25.0%23.0%34.0%43.0%10.0%25.0%11.0%
Total Royalty Revenues Growth — As Reported (YoY %)(%)
12.0%16.0%16.0%16.0%9.0%10.0%4.0%6.0%20.0%8.0%9.0%13.0%
Minjuvi / Monjuvi Net Product Revenue Growth — Constant Currency (CER YoY %)(%)
32.0%72.0%62.0%262.0%79.0%
Minjuvi / Monjuvi Net Product Revenue Growth — As Reported (YoY %)(%)
30.0%72.0%67.0%264.0%87.0%
Niktimvo U.S. Net Product Revenue Growth — As Reported (YoY %)(%)
47.0%67.0%305.0%
Iclusig European Net Product Revenue Growth — Constant Currency (CER YoY %)(%)
-10.0%3.0%8.0%15.0%19.0%16.0%1.0%6.0%-7.0%8.0%-6.0%
Iclusig European Net Product Revenue Growth — As Reported (YoY %)(%)
-11.0%5.0%20.0%25.0%26.0%22.0%-3.0%1.0%7.0%-8.0%10.0%-2.0%
Pemazyre Net Product Revenue Growth — Constant Currency (CER YoY %)(%)
-6.0%5.0%19.0%-1.0%9.0%8.0%6.0%12.0%9.0%-6.0%-22.0%-11.0%
Pemazyre Net Product Revenue Growth — As Reported (YoY %)(%)
-7.0%6.0%22.0%1.0%10.0%9.0%4.0%12.0%-21.0%151.0%33.0%-10.0%
Zynyz Net Product Revenue Growth — Constant Currency (CER YoY %)(%)
158.0%458.0%1,269.0%136.0%608.0%
Zynyz Net Product Revenue Growth — As Reported (YoY %)(%)
157.0%460.0%1,276.0%3,167.0%1,270.0%544.0%136.0%608.0%14.0%
Total Net Product Revenues Growth — As Reported (YoY %)(%)
14.0%40.0%20.0%20.0%19.0%17.0%26.0%18.0%23.0%10.0%5.0%13.0%
Total Consolidated GAAP Revenues Growth — As Reported (YoY %)(%)
14.0%38.0%21.0%28.0%20.0%16.0%20.0%16.0%24.0%9.0%9.0%9.0%
Hematology & Oncology Portfolio Net Product Sales (ex-Jakafi, ex-Opzelura)($M)9
235222204
Hematology & Oncology Portfolio Revenue Growth (YoY %)(%)
38.0%69.0%116.0%
Hematology & Oncology Portfolio Full-Year Net Sales Guidance — Low Bound($M)
890860800800550500415415
Hematology & Oncology Portfolio Full-Year Net Sales Guidance — High Bound($M)
910890880880575520455455
Total Net Product Revenues Full-Year Guidance — Low Bound($M)
5,2105,1304,7704,770
Total Net Product Revenues Full-Year Guidance — High Bound($M)
5,3005,2604,9404,940
Combined GAAP R&D and SG&A Expenses Full-Year Guidance — Low Bound($M)
4,9154,9153,4953,495
Combined GAAP R&D and SG&A Expenses Full-Year Guidance — High Bound($M)
4,9954,9953,6753,675
Combined Non-GAAP R&D and SG&A Expenses Full-Year Guidance — Low Bound($M)
4,6254,6253,2053,205
Combined Non-GAAP R&D and SG&A Expenses Full-Year Guidance — High Bound($M)
4,6954,6953,3753,375
Specialty Distributor Concentration — Customer B Share of Net Product Revenues(%)6
22.0%7.0%8.0%20.0%9.0%10.0%10.0%10.0%11.0%
Specialty Distributor Concentration — Customer C Share of Net Product Revenues(%)
18.0%20.0%21.0%18.0%20.0%20.0%20.0%18.0%18.0%
Specialty Distributor Concentration — Customer D Share of Net Product Revenues(%)
12.0%19.0%19.0%10.0%19.0%19.0%13.0%13.0%12.0%
Specialty Distributor Concentration — Customer E Share of Net Product Revenues(%)
11.0%12.0%10.0%11.0%11.0%9.0%10.0%10.0%10.0%
Specialty Distributor Concentration — Customer A Share of Net Product Revenues(%)
10.0%11.0%13.0%14.0%13.0%14.0%15.0%15.0%17.0%
Major Wholesalers Combined Share of Gross Accounts Receivable(%)
59.0%63.0%64.0%59.0%50.0%51.0%49.0%41.0%40.0%
Novartis & Eli Lilly Combined Royalty Share of Accounts Receivable(%)
14.0%15.0%14.0%17.0%20.0%18.0%16.0%19.0%21.0%18.0%20.0%
Total Gross-to-Net (GTN) Sales Allowance Reserves — Ending Balance($M)9
631534730646607549475446388357366286
GTN Ending Reserve — Commercial & Government Rebates and Chargebacks($M)
526445641562529481407383339309323242
GTN Ending Reserve — Prompt-Pay Discounts & Distribution Fees($M)
46.642.438.638.839.929.229.427.420.021.218.420.5
GTN Ending Reserve — Product Returns Allowance($M)
37.632.132.831.028.826.525.823.017.715.611.711.0
GTN Ending Reserve — Patient Co-Pay Assistance & Other Deductions($M)
21.013.818.114.29.6412.612.513.310.810.613.313.0
Accrued Sales Allowances — Current Liability Portion (Balance Sheet)($M)
624526722642600542468438382350359280
GTN Provisions Recorded for Current-Year Product Sales($M)4
756598691612514511454449391378372344
GTN Provisions (Credits) Recorded for Prior-Year Product Sales($M)3
-1.20-168-58.0-0.43-2.67-3.65-8.644.59-0.764.14-0.510.44
GTN Credits & Payments Settled for Current-Year Product Sales($M)3
630494411522447412270371354363218286
GTN Credits & Payments Settled for Prior-Year Product Sales($M)4
26.913213851.26.6020.714724.25.0528.495.59.90
Total Commercial & Biologics Inventory (Current + Noncurrent)($M)6
476458447443450452429407368356328270
Work-in-Process Drug Substance & Biologics Inventory($M)
356338352344354362352331286285255210
Finished Goods Commercial Inventory($M)
71.470.058.971.864.956.847.548.447.446.749.536.9
Raw Materials Inventory($M)
48.949.836.627.930.733.029.927.635.524.623.423.3
Current Inventory, Net (Balance Sheet)($M)
13411311610183.483.46458.970.410163.663
Noncurrent Multi-Year Biologics & API Inventory (Other Long-Term Assets)($M)
342345331342367368365348298255264207
Pre-Approval Manufacturing Inventory Expensed to R&D (Prior to Regulatory Approval)($M)
32.339.140.943.645.447.427.728.332.334.938.235.6
External Clinical CRO & Contract R&D Expense (ASU 2023-07 Segment Disaggregation)($M)7
271248243272256246193213223224205
Internal R&D Personnel, Lab & Facility Expense (ASU 2023-07)($M)
284269260270250237228250250235223
Upfront Acquired IPR&D, License & Milestone R&D Expense (ASU 2023-07)($M)
1,237012.669.40.1012.615.53.001006801
R&D — Clinical Research & Outside Services (MD&A Natural Breakdown)($M)
317292294390279286229249352248227260
R&D — Salaries, Benefits & Headcount Costs (MD&A)($M)
168146154147147132133131132121123103
R&D — Share-Based Compensation (MD&A)($M)
43.538.239.236.139.737.736.744.245.834.536.836
R&D — Facility Occupancy, Lab Supplies & Other (MD&A)($M)
31.840.428.638.341.139.338.74244.14543.245.3
Collaborative Partner R&D Cost Reimbursements (Contra-R&D Credit)($M)
44.404.405.204.303.904.2017.112.1
Accrued Clinical Trial & CRO Liabilities (Ending Balance)($M)17
16316417817615814613313212110694.6110
U.S. Jakafi Royalties Expensed to Novartis (Cost of Product Revenues)($M)
20.22016.120.319.318.729.837.936.334.62334.1
Accrued U.S. Jakafi Royalty Payable to Novartis($M)
20.22016.120.319.418.7537507470433399376
Syndax U.S. Niktimvo 50% Profit-Share Expense (Cost of Product Revenues)($M)
20.320.214.419.414.3
Syndax Axatilimab Co-Development R&D Expense Recognized by Incyte($M)
4.804.905.405.606.305.304.701.205.804.707.108.90
Accrued Commercialization Payable to Syndax (U.S. Niktimvo)($M)
29.526.522.527.6
Accrued Co-Development Payable to Syndax($M)
1.401.401.402.402.20
Total Accrued Third-Party Royalties — Current Liability($M)
45.042.837.540.736.933.1549520491444410387
Accrued Commercial Sales & Marketing Liabilities($M)
58.960.364.871.248.951.353.833.440.639.542.037.4
Acquisition-Related Contingent Consideration Liability (Level 3 Fair Value)($M)
92102110121184207195193207194202212
Contingent Consideration Financing Cash Payments($M)
4.604.604.964.964.964.965.37
Cumulative Novartis Regulatory Milestones Achieved (Jakavi & Tabrecta)($M)
345345345345345345345345345345345345
Cumulative Novartis Commercial Sales Milestones Achieved($M)
200200200200200200200200200200200200
Cumulative Novartis Development Milestones Achieved($M)
157157157157157157157157157157157157
Cumulative Eli Lilly Regulatory Milestones Achieved (Olumiant)($M)
335335335335335335335335335335335335
Cumulative Eli Lilly Development Milestones Achieved (Olumiant)($M)
149149149149149149149149149149149149
Cumulative Eli Lilly Commercial Sales Milestones Achieved (Olumiant)($M)
505050505050505050505050
Cumulative MacroGenics Milestones Paid (Retifanlimab / Zynyz)($M)
215215215215215215215215215115115115
Commercial Selling & Marketing Expense (ASU 2023-07 Segment Disaggregation)($M)12
297286260308272256258258242229217
General & Administrative Expense (ASU 2023-07 Segment Disaggregation)($M)
67.466.068.581.956.874.768.069.267.376.883.4
Change in Fair Value of Contingent Consideration (Segment Disaggregation)($M)
0.892.50-0.17-28.3-12.222.811.6-4.0423.40.89-0.46
Other Segment Expense & Non-Operating Items (ASU 2023-07)($M)
76.4112-2.2136.619.312547.010039.6-33.5-77.7
Cost of Product Revenues — Partner Royalty Expense (MD&A)($M)
40.838.332.134.230.825.933.740.538.536.925.135.4
Cost of Product Revenues — Drug Manufacturing & Product Costs (MD&A)($M)
32.728.44150.141.130.727.432.238.231.227.425.4
Cost of Product Revenues — Collaboration Profit-Share Expense (MD&A)($M)
20.320.214.419.414.310.3
Cost of Product Revenues — Acquired Product Rights Amortization (MD&A)($M)
776.906.706.90666.106.105.705.705.80
Cost of Product Revenues — Manufacturing Salaries & Benefits (MD&A)($M)
6.7010.29.209.8055.105.2092.602.402.202.50
Cost of Product Revenues — Share-Based Compensation (MD&A)($M)
1.200.900.900.900.900.800.900.700.600.400.600.70
SG&A — Commercial Marketing & Outside Contract Services (MD&A)($M)
217216195243203211205209186181195192
SG&A — Commercial & Corporate Salaries and Benefits (MD&A)($M)
12310810912210594.297.891.391.783.483.278.6
SG&A — Share-Based Compensation (MD&A)($M)
25.128.22425.12126.123.426.931.521.722.423.3
Non-GAAP Adjusted Diluted Net Income (Loss) Per Share($)6
-3.603.091.811.802.261.571.161.431.07-1.820.641.06
Non-GAAP Adjusted Basic Net Income (Loss) Per Share($)
-3.603.211.881.862.331.611.181.461.09-1.820.651.07
Non-GAAP Adjusted Operating Income (Loss)($M)
-630773394451498383284376255161268
Non-GAAP Adjusted Net Income (Loss)($M)
-731643374368456312229281210145239
Non-GAAP Adjusted Cost of Product Revenues($M)
10298.698.311592.772.566.982.480.070.955.063.6
Non-GAAP Adjusted Research & Development Expense($M)
1,7464794775754674564004205251,089388408
Non-GAAP Adjusted Selling, General & Administrative Expense($M)
339324304365308305302300277263277271
Cash Capital Expenditures (Bridged Productive Asset Additions)($M)2
15.612.410.221.914.719.13.1717.45.1954.19.552.27
Capital Expenditures Incurred Included in Accounts Payable & Accruals($M)
0.650.001.634.934.164.052.892.603.540.800.385.05
Cash Payments to Acquire Commercial Product Rights & Intangible Assets($M)
00502500012.51.4000
Property, Plant & Equipment, Gross (Total)($M)8
1,1161,1131,1091,1061,1591,1451,1091,0911,0891,0601,0031,021
PP&E Gross — Buildings & Leasehold Improvements (Wilmington Campus & Yverdon Biologics Plant)($M)
598607609610628627602597585573572585
PP&E Gross — Laboratory & Biologics Manufacturing Equipment($M)
261261260258252250235230232222217221
PP&E Gross — Computer Hardware & Software Systems($M)
171168161152149147160157154152150148
PP&E Gross — Construction in Progress($M)
33.826.725.130.569.757.450.246.160.055.810.813.5
PP&E Gross — Office Furniture & Equipment($M)
24.825.525.324.424.424.423.823.723.823.523.423.4
PP&E Gross — Operating Lease Right-of-Use Assets($M)
15.314.418.319.620.121.922.322.217.318.118.020.6
PP&E Gross — Land (Wilmington Headquarters Campus)($M)
11.011.211.211.316.116.115.515.415.815.410.610.9
Less: Accumulated Depreciation & Amortization($M)
415404389375361346344328316298283270
Total Operating & Finance Lease Liabilities5
Finance Lease Right-of-Use Assets, Net($M)
24.725.626.727.528.229.029.930.825.125.525.525.5
Finance Lease Liabilities — Noncurrent($M)
27.628.429.430.230.931.832.633.528.228.728.929.2
Finance Lease Liabilities — Current($M)
4.134.264.414.524.494.484.484.423.933.873.683.44
Operating Lease Liabilities — Current($M)
5.655.595.605.705.906.176.005.584.354.934.785.69
Finance Lease Principal Cash Payments($M)
1.151.161.181.111.141.161.091.040.980.910.870.88
Marketable Debt Securities — Total Fair Value($M)6
579553555483475467467470467462504443
Marketable Debt Securities — Amortized Cost Basis($M)
586556555481473465466470464464506443
Available-for-Sale Debt Securities Maturing Within 1 Year($M)
212206217189178221257265
Available-for-Sale Debt Securities Maturing in 1 to 5 Years($M)
367348338293297245210205
Purchases of Marketable Debt Securities($M)
72.731.414382.711656.141.229.424.938.3166234
Proceeds from Maturities of Marketable Debt Securities($M)
443269.775.010856.345.523.425.280.410281.6
Noncurrent Restricted Cash($M)
1.761.821.841.851.841.841.671.621.741.631.631.84
Total Share-Based Compensation Expense($M)16
69.867.364.162.161.664.66171.877.956.659.860
Share-Based Compensation — Research & Development($M)
43.538.239.236.139.737.736.744.245.834.536.836
Share-Based Compensation — Selling, General & Administrative($M)
25.128.22425.12126.123.426.931.521.722.423.3
Share-Based Compensation — Cost of Product Revenues($M)
1.200.900.900.900.900.800.900.700.600.400.600.70
Share-Based Compensation — Performance Shares (PSUs)($M)
6.408.4077.102.606.903.1010.912.33.503.403.80
Cash Proceeds from Employee Stock Option Exercises & ESPP($M)
12275.197.916043.414.93.2433.11.2814.50.487.52
Cash Paid for Employee Tax Withholdings on Net Share Settlements($M)
1033.936.9616.350.10.919.450.8932.60.696.170.49
Stock Options Outstanding (Ending Shares, Millions)(M)
8.398.989.7110.912.913.013.112.813.212.912.912.5
Stock Options Outstanding — Weighted-Average Exercise Price($)
87.7085.3685.0783.4682.8382.7183.1383.4583.1684.1584.2985.40
Stock Options Granted (Shares, Millions)(M)
0.850.100.330.090.590.210.530.020.600.130.600.12
Stock Options Granted — Weighted-Average Black-Scholes Fair Value($)
40.6436.5033.3423.5825.0422.6721.5420.1820.67
Stock Options Exercised (Shares, Millions)(M)
1.350.741.321.920.600.020.050.370.020.030.010
Restricted Stock Units (RSUs) Granted (Shares, Millions)(M)
2.040.090.280.072.910.170.350.092.980.080.330.07
Restricted Stock Units (RSUs) Vested & Released (Shares, Millions)(M)
2.290.110.240.361.990.060.450.041.470.050.340.03
Performance Stock Units (PSUs) Vested & Released (Shares, Millions)(M)
0.2800.020.1100
Shares Available for Future Equity Grant Under Stock Incentive Plan (Millions)(M)
5.808.728.799.068.8711.83.164.01410.710.810.8
Anti-Dilutive Potential Common Shares Excluded from Diluted EPS (Millions)(M)
9.242.342.508.1112.411.113.116.113.2
Cash Income Taxes Paid, Net of Refunds($M)
11.915.2-8.7927.07.301770.8470.273.22272.69125
Novartis AG (NVS) — Jakavi Ex-U.S. End-Market Commercial Net Sales($M)2
564576557555539524492487500471478444
Novartis AG (NVS) — Jakavi Commercial Sales Constant-Currency Growth (CER YoY %)(%)
5.0%8.0%5.0%8.0%4.0%8.0%7.0%13.0%18.0%13.0%18.0%14.0%
Novartis AG (NVS) — Jakavi Commercial Sales USD Growth (YoY %)(%)
5.0%10.0%13.0%14.0%8.0%11.0%3.0%10.0%17.0%8.0%15.0%14.0%
Syndax Pharmaceuticals, Inc. (SNDX) — U.S. Niktimvo Quarterly Infusions Administered2
6,3505,7505,0005,0004,500
Syndax Pharmaceuticals, Inc. (SNDX) — 50% Share of U.S. Niktimvo Net Commercial Profit($M)
22.618.115.928.513.99.36-0.25
Syndax Pharmaceuticals, Inc. (SNDX) — Direct External Axatilimab Clinical R&D Expense($M)
7.478.689.639.459.0519.724.28.505.60
U.S. Real Personal Consumption Expenditures — Health Care Services (FRED: DHLCRC1Q027SBEA, Chained $M SAAR)($M)
3,858,6713,790,2923,699,8993,666,9863,614,8543,529,8333,464,6503,417,8343,358,2443,288,2153,244,3553,159,378
Total Consolidated GAAP Revenues($M)7
1,5571,6741,2731,5071,3661,2161,0531,1791,1381,0448811,013
Cost of Product Revenues (GAAP)($M)
1091051051219978.873.288.58676.66169.8
Research & Development Expense (GAAP)($M)
1,7925175166115074954374665731,138429445
Selling, General & Administrative Expense (GAAP)($M)
364352328390329331326327309306300288
Operating Income (Loss) (GAAP)($M)
-708698301336444530205302146-47891.9187
Net Income (Loss) Attributable to Common Stockholders (GAAP)($M)
-785586303299424405158201107-445170201
Diluted Net Income (Loss) Per Share (GAAP)($)
-3.862.811.472.112.040.800.54-2.040.75
Weighted-Average Diluted Shares Outstanding (Millions)(M)
203208207201199198196218227
Net Cash Provided by (Used in) Operating Activities (GAAP)($M)3
-67550836954355944.7266381311-576219148
Total Consolidated Assets (GAAP)($M)
7,2877,8737,3396,9586,3305,8215,7495,4445,0124,6627,1366,782
Total Consolidated Liabilities (GAAP)($M)
1,6441,5281,7161,7911,6791,6512,0821,9971,8411,6651,7411,592
Total Stockholders' Equity (GAAP)($M)
5,6436,3445,6235,1684,6514,1713,6683,4483,1712,9975,3945,190

6 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Incyte Corporation (NASDAQ: INCY, CIK 0000879169) operates on a calendar fiscal year ending December 31 (latest completed fiscal year: FY2025 ended December 31, 2025; latest completed fiscal quarter: Q3 2026 / FY2026Q3 ended September 30, 2026). Incyte manages and reports its global biopharmaceutical operations as a single operating and reportable segment.
  • Commercial operations span three pillars: (1) flagship JAK1/JAK2 inhibitor Jakafi / Jakafi XR (ruxolitinib) in the United States across polycythemia vera (PV), myelofibrosis (MF), and graft-versus-host disease (GVHD) (+12% YoY paid patient demand growth in Q3 2026; FY2026 guidance raised to $3,220M–$3,270M); (2) topical JAK inhibitor Opzelura (ruxolitinib cream) in atopic dermatitis and nonsegmental vitiligo across the U.S. and international markets ($46.9M ex-U.S. sales and +36% YoY global growth in Q3 2026); and (3) the expanding Hematology & Oncology portfolio ($235.0M in Q3 2026, +38% YoY), led by U.S. 50/50 co-commercialized Niktimvo (axatilimab-csfr; ~6,350 infusions administered in Q3 2026 per partner Syndax), wholly-owned global Monjuvi / Minjuvi (tafasitamab), Iclusig, Pemazyre, and Zynyz, alongside royalties from Novartis (ex-U.S. Jakavi: $564M Q3 2026 partner sales; Tabrecta) and Eli Lilly (Olumiant).
  • Key operational disclosures include the 5-column Gross-to-Net (GTN) rebate, chargeback, distribution, return, and co-pay reserve rollforward ($631.5M ending total GTN reserve at September 30, 2026), specialty distributor channel concentration, multi-stage small-molecule & biologics inventory ($475.8M current + noncurrent inventory at Q3 2026), ASU 2023-07 external vs. internal R&D disaggregation, bridged Cash Capital Expenditures across 2018–2026, global workforce & SASB environmental/quality metrics, and standalone UK statutory filings for wholly-owned subsidiary Incyte Biosciences UK Ltd (#08247692; £25.17M turnover and 30 FTEs in FY2025).
  • Under U.S. GAAP, Incyte does not publish standalone parent-only financial statements (Form 10-K omits Schedule I as restricted net assets are immaterial), so no Consolidated − Parent-only subtraction is performed. All metrics are strictly as published (with verbatim hover quotes for text-extracted figures; bound-qualified numbers such as 'Over 400,000 patients' are excluded). The only arithmetic shown in table cells is period splitting from cumulative YTD and full-year disclosures (Q2 = 6M − Q1; Q3 = 9M − 6M; Q4 = full year − 9M), displayed in italic with the formula.

Không hiện vì thiếu các kỳ gần đây (12)

  • Brand-level dollar revenues (Jakafi, Opzelura, Niktimvo, Minjuvi/Monjuvi, Iclusig, Pemazyre, Zynyz), partnered royalty dollar lines (Jakavi, Olumiant, Tabrecta), and consolidated geographic revenues (U.S., Europe, Other Countries) — Already displayed in the Segments section above; excluded here to avoid duplication while retaining non-overlapping Opzelura Ex-U.S. sales, Hematology & Oncology portfolio totals, patient demand YoY %, and CER growth rates.
  • Eli Lilly and Company (LLY) — Olumiant (baricitinib) global end-market commercial sales — Eli Lilly discontinued separate product-line revenue disclosure for Olumiant after Q4 2024, failing the recent 3-quarter continuity requirement.
  • SASB HC-BP-000.A Total Patients Treated ('Over 400,000 patients treated' in the 2025 Global Responsibility Report) — Excluded because management discloses only a bound-qualified figure ('Over ...') rather than a point value.
  • Syndax Pharmaceuticals (SNDX) — U.S. Niktimvo Q1 2025 ('More than 1,250') & Q2 2025 ('>4,000') infusions and quarterly new patient starts ('>300 new patients' in Q4 2025, Q2 2026, Q3 2026) — Bound-qualified disclosures ('>' / 'More than') are excluded; exact point-estimate quarterly infusions (~4,500 to ~6,350 across Q3 2025–Q3 2026) are included.
  • Constant-Currency (CER YoY %) revenue growth for U.S.-only Jakafi & Niktimvo (0.00 percentage point FX variance) and Opzelura & Total Net Product Sales (<1.0 percentage point average FX variance) — Excluded because CER growth adds no incremental FX signal over reported USD YoY % on U.S.-predominant lines.
  • Standalone Full-Year GAAP & Non-GAAP R&D and SG&A Guidance Lines (2019–Q3 2025) — Beginning with initial FY2026 guidance in Q4 2025, Incyte transitioned from separate R&D and SG&A guidance ranges to combined GAAP and Non-GAAP R&D + SG&A guidance.
  • Quarterly Jakafi & Opzelura MD&A Volume vs. Price Dollar Variance (missing Q1 2026 dollar disaggregation) — Excluded due to a gap in Q1 2026 Form 10-Q MD&A narrative.
  • Quarterly Earnings Call Slide Decks on investor.incyte.com (Akamai CDN HTTP 403 block on automated requests) — Operational call metrics were captured instead via Form 8-K Item 2.02 press releases, Form 10-Q/10-K filings, Syndax Form 8-K Exhibit 99.2 investor presentations, and quarterly earnings call transcripts.
  • Global Workforce, Executive Compensation & Sustainability (ESG) › Total Global Full-Time Equivalent Employees › Employees by Region — North America (U.S. & Canada) — Excluded due to insufficient recent consecutive periods.
  • Global Workforce, Executive Compensation & Sustainability (ESG) › Total Global Full-Time Equivalent Employees › Employees by Region — Europe (Including Switzerland & UK) — Excluded due to insufficient recent consecutive periods.
  • Global Workforce, Executive Compensation & Sustainability (ESG) › Total Global Full-Time Equivalent Employees › Employees by Region — Japan — Excluded due to insufficient recent consecutive periods.
  • Global Workforce, Executive Compensation & Sustainability (ESG) › Workplace Safety — Total Recordable Incident Rate (TRIR per 100 FTEs) › Workplace Safety — Lost-Time Incident Rate (LTIR per 100 FTEs) — Excluded due to insufficient recent consecutive periods.

Dữ liệu cập nhật 2026-11-15.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Incyte

See a number that looks wrong?